Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* AIS patients with typical symptoms and signs within 48h, including those who received intravenous thrombolysis for 24 hours.~* The neurologic function deteriorated from 6h to 48h after the onset of the disease, and the NIHSS score increased by ≥ 2 points;~* Sign informed consent.~Exclusion Criteria:~* The diagnosis was cardiogenic cerebral embolism;~* In the patients with large area cerebral infarction of anterior circulation, the focus area was larger than 2 / 3 of the area of cerebral hemisphere;~* Patients with NIHSS score ≥ 21;~* Patients with conversion of intracranial hemorrhage;~* Patients with tirofiban;~* Patients with blood pressure ≥ 180 / 110mmhg after treatment;~* There were severe heart, liver and kidney dysfunction, such as LVEF \< 40%, serum AST and ALT increased to 3 times of the upper limit of normal, creatinine clearance \< 30ml / min;~* Patients with hematological diseases and those with bleeding tendency;~* In the past 6 months, the patients had a history of severe gastrointestinal hemorrhage;~* Allergic to argatraban;~* Patients (such as those with mental and mental disorders) who are not suitable for the clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): Standard medical treatment, including routine antiplatelet, blood pressure control, statins to stabilize plaque, etc.
- Argatroban group (Type: EXPERIMENTAL): Argatraban is used on the basis of standard medical treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).